VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
1 hedge funds and large institutions have $669K invested in VALEANT PHARMACEUTICALS INTL in 2014 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
14% less capital invested
Capital invested by funds: $780K → $669K (-$111K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LWI
Long Wharf Investors
Boston,
Massachusetts
|
-$186K |
| 2 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$18K |
VRX Hedge Fund Activity: Q1 2014 in Review
1 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q1 2014, worth a combined $669K — down 14% from $780K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Long Wharf Investors, cutting an estimated $186K.
- 1 institutional investor held VALEANT PHARMACEUTICALS INTL (VRX) as of Q1 2014, down from 2 in Q4 2013.
- Funds reported $669K of VALEANT PHARMACEUTICALS INTL stock for Q1 2014, down 14% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q1 2014 and 1 closed out, a net change of -1 holder.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q1 2014 was Long Wharf Investors, an estimated $186K sold.
Based on aggregated 13F filings for Q1 2014.